ArticleDermatology practical & conceptual2026
Association Between E-FABP Levels, Disease Severity, and Metabolic Parameters in Hidradenitis Suppurativa.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStudies have shown that hidradenitis suppurativa (HS) is associated with obesity, dyslipidemia, hypertension, metabolic syndrome, and some autoinflammatory diseases. Studies on E-FABP, a member of the fatty acid binding protein family, suggest that this protein may be associated with psoriasis, obesity, metabolic syndrome, atherosclerosis, and autoimmune diseases.
objectivesThe aim of this study was to compare serum E-FABP levels in patients with HS and in healthy control subjects and to investigate the relationship between disease severity and metabolic parameters and serum E-FABP levels.
methodsForty-four HS patients and 45 healthy subjects were included in the study. In the patient and control groups, hs-CRP, routine biochemistry parameters, and serum lipid profiles were measured. Serum E-FABP levels were also determined by ELISA method. Blood pressure, pulse rate, and body measurements were also recorded in the patient and control groups. Obtained data were analyzed with SPSS 22.0.
resultsSerum E-FABP levels were found to be statistically significantly higher in the HS group than in healthy controls. However, no significant correlation was found between serum E-FABP levels and disease severity scores. The effect of E-FABP on the development of HS was determined by multivariate logistic regression analysis independent of age, sex, BMI, and hs-CRP. It was determined that the increase in E-FABP level increased the risk of HS development independently of other risk factors.
conclusionsAccording to this study, E-FABP may be associated with the pathogenesis of HS rather than with disease severity or metabolic conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.